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ABSTRACT
Magnetic resonance imaging (MRI) is a widely used method for the diagnosis of multiple sclerosis that is essential for the de-
tection and follow-up of the disease. 
Objective. The Polish Medical Society of Radiology (PLTR) and the Polish Society of Neurology (PTN) present the second version 
of their recommendations for investigations routinely conducted in magnetic resonance imaging departments in patients with 
multiple sclerosis. This version includes new data and practical comments for electroradiology technologists and radiologists. 
The recommended protocol aims to improve the MRI procedure and, most importantly, to standardise the method of conduc-
ting scans in all MRI departments. This is crucial for the initial diagnostics necessary for establishing a diagnosis, as well as for 
MS patient monitoring, which directly translates into significant clinical decisions. 
Introduction. Multiple sclerosis (MS) is a chronic immune mediated inflammatory demyelinating disease of the central nervous 
system (CNS), the aetiology of which is still unknown. The nature of the disease lies in a CNS destruction process disseminated 
in time (DIT) and space (DIS). MRI detects focal lesions in the white and grey matter with high sensitivity (although with signi-
ficantly lower specificity in the latter). It is also the best tool to assess brain atrophy in patients with MS in terms of grey matter 
volume (GMV) and white matter volume (WMV) as well as local atrophy (by measuring the volume of thalamus, corpus callo-
sum, subcortical nuclei, and hippocampus) as parameters that correlate with disability progression and cognitive dysfunctions.
Progress in MR techniques, as well as advances in postprocessing the obtained data, has driven the dynamic development 
of computer programs that allow for a more repeatable assessment of brain atrophy in both cross-sectional and longitudinal 
studies.
MR imaging is unquestionably the best diagnostic tool available to follow up the course of the disease and support clinicians 
in choosing the most appropriate treatment strategy for their MS patient. However, to diagnose and follow up MS patients on 
the basis of MRI in accordance with the latest standards, the MRI study must adhere to certain quality criteria. Such criteria are 
the subject of this paper.
Key words: multiple sclerosis, magnetic resonance imaging, imaging protocol, guidelines
(Neurol Neurochir Pol 2020; 54 (5): 410–415)
Recommendations for MRI in MS patients 
on MRI scanners with field strength  
at least 1.5T
General comments
Patients with MS are recommended to undergo MRI with 
an intravenous administration of a paramagnetic contrast 
medium (gadolinium) solely as a part of initial diagnostics. 
A follow-up gadolinium-enhanced MRI with the use of 
macrocyclic contrast agents is recommended only in cases of 
a clinical progression of the disease, or if the need arises for 
another differential diagnosis of MS, or in another clinically 
justified situation. The retention characteristics of each gad-
olinium-based contrast agent (GBCA) should be considered 
in all patients; linear GBCAs have been shown to result in 
greater retention, and retention for longer, than macrocyclic 
GBCAs. This is why the use of linear contrast agents based on 
gadolinium (GBCA) is not recommended in following up the 
treatment of MS in clinically and radiologically stable patients, 
due to the potential occurrence of long-term side effects asso-
ciated with the accumulation of contrast agent within the CNS. 
Patients with clinically isolated syndrome (CIS) or sus-
pected MS should undergo:
 — Head MRI before and after an intravenous administration 
of a contrast agent (Tab. 1).
 — It is recommended that an additional scan of the cervical and 
thoracic sections of the spinal cord (in accordance with the 
referral/indication of the neurologist) is performed after an 
intravenous administration of a contrast agent, especially when 
head MRI does not meet the diagnostic criteria or when clinical 
symptoms suggest the lesions are located in the spinal cord (Tab. 
2). Ideally, MRI studies of the head and the cervical/thoracic 
spine should be performed within a single MRI imaging session.
MRI of the spinal cord is particularly important in the 
diagnosis of primary progressive MS according to the current 
disease diagnosis criteria (Tab. 3).
In patients with multifocal damage to the nervous system 
involving symptomatology associated with both brain and spinal 
cord impairment, in order to shorten the diagnostic time, (and 
according to the referring neurologist’s recommendations) it is 
possible to perform simultaneously an MRI of the head and of a se-
lected section of the spinal cord using a combined protocol (Tab. 4).
Recommendations for disease progression follow-up 
based on MRI:
 — Head MRI to show new/enlarging demyelinating lesions 
(Tab. 1) at least every 12 months during the initial years 
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Table 1. Head MRI protocol 
Parameters Description
Electromagnetic field Images should be of good quality with an appropriate SNR value and resolution (≤ 1x1 mm)
Reference setting When setting the scanning plane, use a line parallel to the lower edges of the rostrum and splenium of the corpus callo-
sum; also have an identical angulation of the planned slices to that of the slices in the previous study (Fig. 1)
Scanning range Whole brain scanned
Slice thickness and gaps ≤ 3 mm, with no gaps (for 2D and 3D acquisition)
Basic sequences 1. 3DT1 axial isotropically
2. T2 axial
3. DWI axial (with ADC map)
Administration of a contrast medium1 (T1 sequence 5–10 minutes after administration)
4. FLAIR+C sagittal
5. FLAIR+C axial
6. 3DT1+C axial isotropically2
1The recommended dose of a contrast medium is 0.1 mmol/kg body mass; see General Comments.
2It is recommended to perform and record sagittal reconstructions and archive them on a CD (and in the PACS system if 
available), as an integral part of the examination
Optional sequences 1. PD
2. SWI – to identify central veins in lesions and microbleedings
3. DIR – to evaluate cortical and subcortical foci
SNR — signal-to-noise ratio; 2D — two-dimensional; 3D — three-dimensional; DWI — diffusion-weighted imaging; ADC — apparent diffusion coefficient; FLAIR — fluid-attenuated inversion recovery sequen-
ce; +C — postcontrast; PD — proton density; SWI — susceptibility weighted imaging; DIR — double inversion recovery; PACS — picture archiving and communication system
Table 2. Spinal cord section MRI protocol 
Parameters Description
Electromagnetic field Images should be of good quality with an appropriate SNR value and resolution (≤ 1x1 mm)
Scanning range Spinal cord section scanned
Slice thickness and gaps Sagittal: ≤ 3 mm, no gaps (for 2D and 3D)
Axial: 3 mm, no gaps
Basic sequences 1. T2 sagittal 
2. T1 sagittal 
Administration of a contrast medium1 (T1 sequence 5–10 minutes after administration)
3. STIR/T2 FAT-SAT, PD or PST1-IR+C sagittal
4. T2+C axial at the level of the lesions visible in sagittal sequences
5. T1+C sagittal
6. T1+C axial
1The recommended dose of a contrast medium is 0.1 mmol/kg body mass; see General Comments
Optional sequences 1. T2 coronal at the level of the lesions visible in the other sequences
2. 3DT1 sagittal (to assess spinal cord atrophy)
SNR — signal-to-noise ratio; 2D — two-dimensional; 3D — three-dimensional; STIR — short tau inversion recovery; FAT-SAT — fat saturation; PD — proton density; PST1-IR — phase-sensitive T1-weighted 
inversion-recovery; +C — postcontrast 
of treatment, but possibly less frequently later in patients 
with complete clinical stability.
 — Cervical and/or thoracic spinal cord scan is recommended, 
according to the neurologist’s referral/indication.
For patients under the age of 18, the MRI protocol for brain 
and spinal cord examination remains unchanged; examination 
is the same as in the adult population.
Brain MRI protocol for MS patients
In order to use the same scanning planes during the fol-
low-up examinations, it is recommended to achieve slices in 
the true midline plane.
For this purpose, once three localisation slices have been 
performed, five slices with a thickness of 3 mm should be 
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Marek Sąsiadek et al., Recommendations of the Polish Medical Society of Radiology and the Polish Society of Neurology 
Table 4. Head and spinal cord section MRI protocol (combined) 
Parameters Description
Electromagnetic field Images should be of good quality with an appropriate SNR value and resolution (≤ 1x1 mm)
Scanning range Brain and spinal cord scanned
Slice thickness and gaps Head and spinal cord (sagittal) ≤ 3 mm, no gaps (for 2D and 3D) 
Spinal cord (axial): 3 mm, no gaps
Basic sequences 1. Use protocol prior to the administration of a contrast medium for the head 
 Administration of a contrast medium1 (T1 sequence 5–10 minutes after administration)
2. FLAIR+C sagittal (head)
3. FLAIR+C axial (head)
4. 3DT1+C axial isotropically (head)2
5. T2+C sagittal (spinal cord section)
6. STIR/T2 FAT-SAT, PD or PST1-IR+C sagittal (spinal cord section)
7. T2+C axial at the level of the lesions visible in sagittal sequences (spinal cord section)
8. T1+C sagittal (spinal cord section)
9. T1+C axial (spinal cord section)
1The recommended dose of a contrast medium is 0.1 mmol/kg body mass; see General Comments.
2It is recommended to perform and record sagittal reconstructions and archive on a CD (and in the PACS system if availab-
le), as an integral part of the examination
Optional sequences As in the specified protocols of the head and spinal cord
SNR — signal-to-noise ratio; 2D — two-dimensional; 3D — three-dimensional; FLAIR — fluid-attenuated inversion recovery sequence; STIR — short tau inversion recovery; FAT-SAT — fat saturation; PD — pro-
ton density; PST1-IR — phase-sensitive T1-weighted inversion-recovery; +C — postcontrast; PACS — picture archiving and communication system
Table 3. 2017 McDonald criteria for MS diagnosis
Clinical presentation Additional criteria required for diagnosis 
Minimum two relapses, clinical signs from 
two foci
Not required*
Minimum two relapses, clinical signs from 
one focus
DIS damage to the nervous system on MRI or another relapse of different clinical location
One relapse, clinical signs from two or 
more foci
DIT damage to the nervous system on MRI, or presence of specific oligoclonal bands in cerebrospinal 
fluid (absent in serum) or subsequent relapse
One relapse, clinical signs from one focus 
(isolated CNS damage)
DIS and DIT damage to the nervous system on MRI, or presence of specific oligoclonal bands (absent in 
serum) in cerebrospinal fluid 
Primary progressive MS One year of neurological disability progression diagnosed prospectively or retrospectively, and two of 
the following conditions fulfilled: 
1. MRI dissemination in space (but one and not two typical locations required)
2. MRI dissemination in space in the spinal cord (minimum of two lesions) 
3. Positive CSF test (presence of oligoclonal bands, absent in serum, and/or elevated immunoglobulin 
index)
*Once other possible causes of symptoms have been excluded; in practice, every patient with suspected MS should undergo as a minimum an MRI of the head and spinal cord as well as a lumbar puncture
planned as accurately as possible in the sagittal plane on 
T2-weighted images. 
The planned slices should be set parallel to the longitudinal 
cerebral fissure using the localisation slices, in the transverse 
and frontal planes. The third of these five slices should pass 
through the median fissure as accurately as possible. 
Cross-sectional slices should be set on the thereby obtained 
midline slice in parallel to the lower limits of the rostrum (an-
terior commissure, AC) and splenium of the corpus callosum 
(posterior commissure, PC), according to the AC-PC reference 
line (Fig. 1).
Note: During the follow-up examinations, when the scan-
ning plan is set in the reference to the corpus callosum, it is 
vital to compare the angulation of the planned slices with the 
angulation of the slices in the previous study. 
Some scanners do not have the possibility of remembering 
a single slice; in such case the slice should be carefully defined 
as shown in Figure 1.
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Figure 1. A pre-specified reference line parallel to the corpus callosum
Table 5. DIS and DIT damage to the nervous system according to the 2017 McDonald criteria 
Damage to the CNS disseminated  
in space (DIS)
Damage to the CNS disseminated in time (DIT) 





4. Spinal cord 
Occurrence of new lesions on T2-weighted images and/or contrast-enhanced lesions on a subsequent 
MRI scan compared to a reference examination, regardless of the time elapsed since the baseline exami-
nation, 
or 
concomitant occurrence of contrast-enhancing and non-enhancing lesions, regardless of the time of this 
examination in relation to the time of the onset of neurological signs and symptoms (may also be a basic 
examination), 
or
immunological equivalent of radiological dissemination over time: confirmation of the presence of 
specific oligoclonal bands (absent in serum) in the cerebrospinal fluid
Note:
1. The direction of scanning in axial scans must be upwards, 
whereas in sagittal scans it must be from right to left (also 
when scanning spinal cord).
2. Gaps between slices should be as small as possible (we 
propose 0.3 mm, i.e. 10% slice thickness or no gap).
3. 3DT1 — we recommend performing this sequence first, to 
avoid motion artifacts in the course of the examination. This 
sequence allows for precise volumetric evaluation of the 
brain.
4. Both FLAIR sequences should be performed after the 
administration of a contrast medium, to delay the onset 
of T1+C acquisition (within the range of 5–10 minutes) in 
order to achieve better contrast enhancement. A contrast 
medium does not lessen the quality of FLAIR images. 
At the same time, the patient’s time spent in the scanner 
is used optimally. The possible enhancement of cortical 
demyelinating lesions or leptomeninges does not affect 
study interpretation, because enhancement is in any case 
assessed on the basis of T1-weighted sequences.
5. If scanning with 3DT2 and 3DFLAIR sequences, if possible 
they should be done in the sagittal plane and should be used 
with subsequent cross-reconstruction with 3 mm slices in the 
plane set up to the lower edge of the corpus callosum. When 
scanning in this way, clinicians should consider conducting 
the 3DT2 sequence scan after a contrast medium injection, 
so as to ensure an appropriate delay in T1 acquisition.
6. If software which automatically determines the angula-
tion/range of the layers can be used, as in the previous 
examination, such a function is recommended.
A radiological report should include standard terminology 
used in brain assessment.
Description of focal lesions:
1. Location (supratentorial region: cortical, juxtacortical, 
central white matter, periventricular, infratentorial, corpus 
callosum, brainstem, spinal cord). 
2. Size — the range of the longest dimension provided i.e. 
from–to. In the case of multiple lesions, report the size of 
the largest lesion only (in mm). According to the current 
definition, demyelinating lesions are defined as lesions of 
≥ 3 mm in diameter.
3. The number of demyelinating lesions – specify according 
to the following scheme: 1, 2, 3–8, ≥ 9.
4. The nature of the lesion, i.e. specify whether the appear-
ance is typical for MS demyelination, or whether differ-
ential diagnosis is required, e.g. ischaemic lesion.
5. Whether the lesions are disseminated in space (DIS) and 
meet the 2017 McDonald criteria (Tab. 3 and Tab. 5).
6. Comparison with the previous head and spinal cord MRI 
(if available). In patients with suspected MS, comparison 
with the previous MRI to assess disease activity and eligi-
bility for treatment. In on-treatment patients, comparison 
with the previous examination and baseline examination 
performed prior to treatment initiation. 
7. Activity assessment, i.e. the number of contrast-enhancing 
foci in the current examination and the number of new/
enlarging lesions compared to the baseline and the previ-
ous examination. Please specify according to the scheme: 
1, 2, 3–8, ≥ 9.
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8. Assessment of brain atrophy. We recommend avoiding 
expressions such as “brain atrophy” or “cerebral atrophy” in 
the report. If possible, provide current whole brain volume, 
grey matter volume, white matter volume, corpus callosum 
volume, and the volume of the right and left thalami. 
There is a growing need for volumetry assessment in MS 
patient imaging, because it potentially can change treatment 
decisions. Many important factors influence volumetric cal-
culations, including acquisition parameters, intrascanner var-
iability, pseudoatrophy, and patient hydration or movement. 
Having appropriate 3DT1 sequences in the protocol makes 
it possible to use software available on the market that can 
measure patient atrophy over time. Volumetric applications 
differ in the range of output results, and cost is another very 
important factor. This is why volumetric analysis of the brain 
should be performed using certified software, and preferably 
by a central institution in order to standardise results.
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